Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

the Company's filings with the Securities and Exchange Commission.

    APPENDIX
    1. Principal Risks and Uncertainties
    RISKS RELATED TO THE GROUP'S BUSINESS
    The Group's new products may not be a commercial success

Shire has launched a number of new products in the last four years, including key new products ELAPRASE, VYVANSE, LIALDA, FIRAZYR and FOSRENOL (Rest of World ('ROW')). The commercial success of these new products, as well as other new products that the Group may launch in the future, will depend on their approval and acceptance by physicians, patients and other key decision-makers, as well as the timing of the receipt of marketing approvals, the scope of marketing approvals as reflected in the product's label, the countries in which such approvals are obtained, the authorization of price and reimbursement in those countries where price and reimbursement is negotiated, and safety, efficacy, convenience and cost-effectiveness of the product as compared to competitive products.

The Group may not be able to grow revenues in its new products as quickly as anticipated if any or all of the following occur:

    - if competitive products are genericised and the impact on the market
      negatively affects the prescribing of branded treatments for the
      indications that the Group's new products treat;

    - if there are unanticipated adverse events experienced with the Group's
      new products not seen in clinical trials that impact the physician's
      willingness to prescribe the Group's new products;

    - if issues arise from clinical trials being conducted for post marketing
      purposes or for registration in another country or regulatory agencies
      in one country act in a way that causes concern for prescribers or
      patients in another country;

    - if patients, payors or physicians favor older treatments over newer
      treatments;

    -
'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... ROCKVILLE, Md. , Sept. 30, 2014 /PRNewswire/ ... "RegeneRx") today announced that it has received a ... Aging by Actin-Sequestering Peptides.  This patent includes claims ... and numerous other actin-sequestering peptides for these purposes.  ... About RegeneRx Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
(Date:9/30/2014)... 30, 2014 Fast, semi-automatic ... chemistry in documents ChemAxon , ... consulting services for life science research, launches ChemCurator, ... Markush structures from documents. Markush structures ... however generating and understanding Markush structures is a ...
(Date:9/30/2014)... Los Angeles, CA (PRWEB) September 30, 2014 ... Separation (EWS), the high-speed, chemical-free process to clean up ... letter to shareholders, CEO Riggs Eckelberry reported on the ... West Texas, at a site provided by partner ... ramped up to 1000 barrels per day (bpd) and ...
(Date:9/30/2014)... BioHealth Innovation, Inc. (BHI), a ... and increasing access to early-stage funding in ... Tania Fernandez , Ph.D., has joined the BHI ... a member of the management team for a new ... million in seed and early-stage equity investments to therapeutics, ...
Breaking Biology Technology:RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2Seasoned Life Sciences Venture Capitalist Tania Fernandez Joins BHI to Help Manage New BioHealth Gap Fund 2
... FULTON, Miss., March 20, 2012  Frank A. Critz, M.D., founder ... honored with a hometown hero,s welcome this April when he ... prostate cancer survivors.  The event will be April 14, 2012 ... Street in Fulton from noon until 3 p.m., and lunch ...
... DIEGO, March 20, 2012   CareFusion announced today ... Food and Drug Administration (FDA) for its new electrodiagnostic ... EDX system is a multi-modality device for monitoring and ... system. (Logo: http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO ) ...
... LAKE CITY, March 20, 2012 Remedy Informatics, the ... research, announced that Renton, Wash.-based Providence Health & ... registries for their Orthopedic Institute and Telestroke Network to ... http://photos.prnewswire.com/prnh/20120206/SF47874LOGO ) "We are excited to work ...
Cached Biology Technology:Radiotherapy Clinics of Georgia's Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award 2CareFusion Announces 510(k) Clearance and U.S. Launch of New Advanced Electrodiagnostic System 2Providence Health & Services Inks Deal with Remedy Informatics for Orthopedic and Stroke Registries 2Providence Health & Services Inks Deal with Remedy Informatics for Orthopedic and Stroke Registries 3
(Date:9/30/2014)... any aquatic environment on Earth, but when the climate ... to the limit. The amount of time needed to ... different species cope in the future, reveals a new ... in the scientific journal Proceedings of the Royal ... to increasing levels of greenhouse gases in the atmosphere. ...
(Date:9/30/2014)... in Munich report that a new class of ... chemotherapeutic drugs. They have also pinpointed the relevant ... anti-tumor agents. , Researchers led by LMU,s ... the Technische Universitt Mnchen have identified a class ... in the fight against malignant tumors. The compound ...
(Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... 2012) - The many factors that contribute to how cells ... not fully understood, but researchers at Baylor College of ... intracellular membranes fuse, and in the process, created a new ... the current edition of the journal PLoS Biology . ...
... Cytori Therapeutics (NASDAQ: CYTX) announced today the publication ... Company,s European clinical trial evaluating adipose-derived stem and ... infarction (heart attack or AMI), as Research Correspondence ... of Cardiology . The APOLLO trial was a ...
... (NAS) has awarded John Waterbury, scientist emeritus in the ... the 2012 Gilbert Morgan Smith Medal. Waterbury is ... recognition of their extraordinary scientific achievements in a wide ... sciences. The recipients will be formally recognized in a ...
Cached Biology News:Membrane fusion a mystery no more 2Adipose stem cell heart attack trial data published in JACC 2WHOI's John Waterbury receives NAS Gilbert Morgan Smith Medal 2
... is a 96-well ELISA-compatible plate containing ... (mouse IgG 1 ) is directed ... (GST), and binds with high affinity ... in which the tag is exposed. ...
... Laboratory (RTL) can provide you with ... ,,Microbial method development and validation ,Performance ... conditions of your GMP manufacturing environment ... offer a full spectrum of microbiological ...
... years of experience in the development of ... to large and small peptides, proteins, haptens, ... DNA-encoded antigens. We understand and appreciate that ... development programs are never "cookbook". We will ...
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
Biology Products: